Perrigo Cuts 2026 Sales Outlook After Core Sales Slip 1.7%
PRGO sits 75% above its 52-week low of $9.225.
Summary
Perrigo's Q3 sales of $989 million edged past the $987.20 million consensus, but core net sales fell 1.7% year over year as retailers kept inventory lean ahead of cough and cold season and contract manufacturing volumes dropped. Share gains in U.S. store-brand OTC and key European brands only partly offset the pressure. The company cut its 2026 core net sales growth outlook to a range of (3.6)% to (2.5)% and guided core adjusted EPS to $2.15-$2.35 with a 14.0%-15.0% core adjusted operating margin. This follows the October 29 agreement to sell the infant formula business to MeridianMade for up to $175 million, part of the push to concentrate on self-care. The sales beat is thin and the guidance cut is the bigger item for a stock trading near $16 against a $16.50 median price target.
At the time of this announcement, PRGO was trading at $16.15 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $9.23 to $20.65. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.